Discordant expression rates can be observed in a not irrelevant quota of patients and varies from 9–30% for ER, 15–45% for PR and 4–16% for HER2 expressions, and can affect tumor behavior and treatment response [49,50,51,52,53,54,55,56,57]. This evidence concerns the gene ERBB2 and neoplasm.